BPS Cardiology Pharmacy Certification Examination Practice Test
Cardiology pharmacy practice applies pharmacotherapy and monitoring to cardiovascular conditions, including heart failure, coronary disease, hypertension, arrhythmias, and lipid disorders. The available questions use patient scenarios involving medication effects, laboratory findings, hemodynamic status, and treatment decisions. They offer practice in identifying when a cardiovascular regimen may need review or when a patient’s clinical stability affects therapy.
Exam overview
About the BPS Cardiology Pharmacy Certification Examination Exam
Clinical decisions in cardiology pharmacy require connecting a diagnosis and current status with the benefits and risks of medication therapy. Scenarios may involve recognizing orthostatic symptoms or bradycardia as possible medication effects, assessing when to initiate or titrate heart-failure treatment, and considering anticoagulation strategies around cardioversion. Other questions address monitoring for electrolyte changes with diuretics, evaluating muscle symptoms during statin therapy, and understanding how ACE inhibitors affect blood pressure. These tasks draw on interpretation of vital signs and laboratory results, medication reconciliation, adverse-effect assessment, and patient-specific risk evaluation. They also require distinguishing stable disease from conditions that call for cautious treatment changes, such as severe aortic stenosis or symptomatic hypotension.
Sample Practice Questions
Review a selection from this exam's published US Practice Tests practice bank.
A patient with heart failure is taking a loop diuretic and reports lightheadedness when standing. Blood pressure falls substantially from sitting to standing, and there is no evidence of congestion. Which medication issue should be reviewed first?
Show answer
Correct answer: AOrthostatic symptoms in a patient without congestion may be related to excessive diuresis and reduced intravascular volume. The regimen and volume status should be assessed before changing therapy. Increasing the diuretic or stopping all heart-failure treatment without evaluation is inappropriate.
A patient with chronic stable coronary disease takes metoprolol and has a resting heart rate of 54 beats/min with dizziness. Which action is most appropriate to address a possible medication-related cause?
Show answer
Correct answer: ABeta blockers can cause bradycardia and contribute to dizziness. Symptomatic bradycardia warrants clinical assessment and review of the dose and other contributing medications. Increasing the dose or combining with another rate-slowing agent without assessment could worsen the problem.
A patient with HFrEF is taking an evidence-based beta blocker. Which finding is the best reason to defer starting or increasing the dose until the patient is stabilized?
Show answer
Correct answer: ABeta blockers with proven HFrEF benefit should generally be initiated or titrated when the patient is clinically stable and not markedly volume overloaded or dependent on intravenous inotropes. Starting or increasing therapy during hemodynamic instability can worsen cardiac output or decompensation.
A patient with atrial fibrillation is being considered for elective cardioversion after an episode of uncertain duration. Which general strategy helps reduce the risk of thromboembolism around cardioversion?
Show answer
Correct answer: AFor atrial fibrillation of prolonged or uncertain duration, anticoagulation is generally used before cardioversion and continued afterward according to guideline-based timing and patient risk. Restoring sinus rhythm does not itself eliminate thromboembolic risk. Rate-control drugs and aspirin are not substitutes for indicated anticoagulation.
A patient with hypertension is prescribed a thiazide-type diuretic. Which laboratory abnormality is a recognized potential adverse effect that may require monitoring?
Show answer
Correct answer: AThiazide-type diuretics can cause hyponatremia and other electrolyte changes, including hypokalemia. Electrolyte monitoring is particularly relevant after initiation or dose changes and in patients with additional risk factors.
A patient with HFrEF and sinus rhythm has a resting heart rate of 78 beats/min despite a maximally tolerated beta blocker. The patient is taking other guideline-directed therapy and has had a heart-failure hospitalization within the past year. Which medication may be considered to reduce heart-failure hospitalization risk?
Show answer
Correct answer: AIvabradine slows the sinus rate through inhibition of the If current. It may reduce heart-failure hospitalization in selected patients with symptomatic HFrEF, sinus rhythm, and an elevated resting heart rate despite maximally tolerated beta-blocker therapy. Non-dihydropyridine calcium-channel blockers such as diltiazem and verapamil can worsen systolic heart failure.
A patient with severe aortic stenosis is being evaluated for treatment of hypertension. Why should medications that markedly reduce preload or afterload be introduced cautiously and individualized?
Show answer
Correct answer: AIn severe aortic stenosis, excessive reductions in preload or systemic blood pressure can compromise cardiac output and perfusion. Hypertension can still require treatment, but medication selection and titration should be individualized and monitored.
How to use this practice test
Access is free. A session presents up to 20 random questions from the 50-question practice bank, with results shown after the session. Use the scenarios to test medication-safety reasoning, connect clinical findings with possible drug effects, and identify which decision points need further review.
Preparation tips
- For heart-failure scenarios, distinguish congestion from volume depletion and connect blood pressure, symptoms, and heart rate to decisions about diuretics or beta-blocker titration.
- Review the purposes and clinical context of guideline-directed HFrEF therapies, including when ivabradine may be considered for persistent elevated heart rate in sinus rhythm.
- Practice linking anticoagulation strategies to atrial fibrillation and cardioversion, especially when episode duration is uncertain.
- Match common cardiovascular medications with monitoring needs, such as electrolytes during diuretic therapy and creatine kinase assessment when significant statin-associated muscle injury is suspected.
- Consider hemodynamic risks in structural heart disease, including why blood-pressure treatment in severe aortic stenosis may require cautious, individualized changes.